EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparison of the Efficacy and Safety of PD ‐1/ PD ‐ L1 Inhibitors in the Treatment of Small Cell Lung Cancer

Qichen Zhang, Xiaojuan Han, Jiayi Liu, Hui Qiao

Cancer Reports · 2025

DOI: 10.1002/cnr2.70081 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cancer Reports, 2025. Verfasst von Qichen Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: The First Clinical Medical College of Lanzhou University, Lanzhou, China. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Immune Checkpoint Inhibitors, Programmed Cell Death 1 Receptor. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lanzhou Science and Technology Bureau 2023 Science and Technology Plan Project, Construction Project of Clinical Medical Research Center from Gansu Provincial Department of Science and Technology, Gansu Science and Technology Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aims to evaluate the efficacy and safety of PD‐1/PD‐L1 inhibitors in treating small‐cell lung cancer (SCLC) and determine the role of PD‐1 monoclonal antibodies in improving patient outcomes.

Methods

A retrospective analysis was performed on 37 SCLC patients who received PD‐1 or PD‐L1 inhibitors along with chemotherapy at the First Hospital of Lanzhou University between June 2018 and June 2023. Treatment effectiveness was measured by overall response rate (ORR), disease control rate (DCR), overall survival (OS), and progression‐free survival (PFS), utilizing chi‐square and T‐tests, along with Kaplan–Meier and log‐rank analyses.

Results

In the PD‐L1 group, 16 patients achieved partial or complete response, versus 12 in the PD‐1 group, though the difference in the ORR was not statistically significant (50.0% vs. 36.8%, p = 0.308). Median survival times were 21.0 months for PD‐L1 and 17.0 months for PD‐1, with no statistically meaningful difference ( p = 0.180). Adverse effects were comparable between the groups in terms of thyroid function ( p = 0.898), but bone marrow suppression and gastrointestinal reactions were significantly less severe in the PD‐L1 group ( p = 0.047 and p = 0.002).

Conclusion

Immunotherapy combined with chemotherapy offers significant benefits for advanced SCLC patients, irrespective of the type of inhibitor used. Despite the higher incidence of adverse reactions with PD‐1 inhibitors, they remain a viable option, particularly when PD‐L1 inhibitors are not available, due to their manageable safety profile and effective response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaLung NeoplasmsImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorB7-H1 AntigenAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleRetrospective StudiesMiddle AgedAgedAdultTreatment OutcomeProgression-Free SurvivalAged, 80 and over

Stichwörter der Autor:innen

PD‐L1/PD‐1adverse reactionsefficacy evaluationsmall cell lung cancer (SCLC)

Substanzen

Immune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorB7-H1 AntigenPDCD1 protein, humanCD274 protein, human

Autor:innen und Institutionen

  • The First Clinical Medical College of Lanzhou University, Lanzhou, China.
  • Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, China.
  • Gansu Province Clinical Research Center for Thoracic Tumor, Lanzhou, China.

Förderung

  • Lanzhou Science and Technology Bureau 2023 Science and Technology Plan Project
  • Construction Project of Clinical Medical Research Center from Gansu Provincial Department of Science and Technology
  • Gansu Science and Technology Project
  • The First Hospital of Lanzhou University Hospital Fund
  • Longyuan Youth Innovation and Entrepreneurship Talent Team Project in 2022 from the Organization Department of CPC Gansu provincial Party committee

Zitieren

APA

Zhang, Q., Han, X., Liu, J., & Qiao, H. (2025). Comparison of the Efficacy and Safety of PD ‐1/ PD ‐ L1 Inhibitors in the Treatment of Small Cell Lung Cancer. Cancer Reports. https://doi.org/10.1002/cnr2.70081

Vancouver

Zhang Q, Han X, Liu J, Qiao H. Comparison of the Efficacy and Safety of PD ‐1/ PD ‐ L1 Inhibitors in the Treatment of Small Cell Lung Cancer. Cancer Reports. 2025. doi:10.1002/cnr2.70081

BibTeX
@article{Zhang2025,
  author = {Zhang, Qichen and Han, Xiaojuan and Liu, Jiayi and Qiao, Hui},
  title = {Comparison of the Efficacy and Safety of PD ‐1/ PD ‐ L1 Inhibitors in the Treatment of Small Cell Lung Cancer},
  journal = {Cancer Reports},
  year = {2025},
  doi = {10.1002/cnr2.70081}
}
Kostenlos starten →